SER
HEALTHCARESerina Therapeutics Inc
What's Moving SER Today?
No stock-specific AI insight has been generated for SER yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.92
Fundamentals
Trading
SER News
21 articles- Serina Therapeutics Announces Completion of Merger with AgeX TherapeuticsGlobeNewswire·Jun 18, 2026
- Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesYahoo Finance·May 14, 2026
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionYahoo Finance·May 13, 2026
- Serina Therapeutics to Present at the 5th LNP Formulation & Process Development SummitGlobeNewswire Inc.·Apr 7, 2026
- Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance PlanYahoo Finance·Apr 2, 2026
- Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business HighlightsYahoo Finance·Mar 25, 2026
- Serina Therapeutics to Present at the 38th Annual Roth ConferenceYahoo Finance·Mar 24, 2026
- Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s DiseaseYahoo Finance·Mar 18, 2026
- Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s DiseaseYahoo Finance·Feb 24, 2026
- Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's DiseaseYahoo Finance·Feb 19, 2026
- Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar EventYahoo Finance·Feb 3, 2026
- Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s diseaseYahoo Finance·Jan 28, 2026
- Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' EquityYahoo Finance·Jan 15, 2026
- Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of ChemistryYahoo Finance·Dec 11, 2025
- Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 ProgramYahoo Finance·Dec 10, 2025
- Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business HighlightsYahoo Finance·Nov 13, 2025
- Serina Therapeutics Provides Regulatory Update on SER-252 ProgramYahoo Finance·Nov 3, 2025
- Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and InvestorsYahoo Finance·Oct 8, 2025
- Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s DiseaseYahoo Finance·Oct 6, 2025
- Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s DiseaseYahoo Finance·Sep 9, 2025
- Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Sep 8, 2025
All 21 articles loaded
Price Data
52-Week Range
$1.92
Fundamentals
Trading
About Serina Therapeutics Inc
Serina Therapeutics Inc is a pioneering biotechnology company focused on developing innovative solutions for unmet medical needs in oncology and neurology through its proprietary polymer-based drug delivery platform. This technology significantly enhances the efficacy of therapeutic agents, positioning Serina at the forefront of the biopharmaceutical industry. With a promising pipeline of product candidates and strategic partnerships, the company is well-equipped to drive sustainable growth and deliver impactful healthcare solutions, all while creating substantial value for its investors.